Servicio de Oftalmología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
Servicio de Oftalmología, Hospital Universitario 12 de Octubre, Madrid, Spain.
Arch Soc Esp Oftalmol (Engl Ed). 2022 May;97(5):286-289. doi: 10.1016/j.oftale.2022.02.006. Epub 2022 Feb 26.
Mitogen-activated protein kinase kinase (MEK) inhibitors have significantly improved the prognosis of various types of cancer such as metastatic melanoma. However, their use is usually associated with ocular side effects. A retinopathy associated with these agents (MEKAR) has been described, consisting of the development of neurosensory detachments, generally bilateral and multiple, similar to those that appear in the central serous chorioretinopathy (CSC). Generally, optical coherence tomography allows us to differentiate the two conditions. We present the case of a 55-year-old woman in treatment with a MEK inhibitor, who developed bilateral neurosensory detachments and blurred vision, which resolved with the discontinuance of the treatment due to tumour progression.
丝裂原活化蛋白激酶激酶（MEK）抑制剂显著改善了转移性黑色素瘤等多种类型癌症的预后。然而，它们的使用通常与眼部副作用相关。这些药物相关的视网膜病变（MEKAR）已经被描述，包括神经感觉脱离的发展，通常是双侧和多发性的，类似于在中心性浆液性脉络膜视网膜病变（CSC）中出现的那些。通常，光学相干断层扫描可以帮助我们区分这两种情况。我们报告了一例 55 岁女性在接受 MEK 抑制剂治疗时出现双侧神经感觉脱离和视力模糊，由于肿瘤进展，中断治疗后这些症状得到缓解。
